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Rechallenge with temozolomide in patients with recurrent
gliomas
Abstract
Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as
well as those with recurrent anaplastic glioma (AG) and GBM. It has become common practice to
re-expose patients to TMZ who had been previously treated with TMZ, or to switch patients to
alternative dosing regimens of TMZ when there are signs of relapse or progress on standard TMZ
therapeutic regimens. To date, however, there is a scarcity of data on the efficacy of this therapeutic
strategy, currently referred to as TMZ rechallenge. We have conducted a retrospective review of patients
with recurrent glioma rechallenged with TMZ. Patients experiencing progressive disease (PD) during
TMZ therapy who were rechallenged with alternative TMZ regimens and patients rechallenged after
stable disease in a TMZ-free interval were evaluated separately. A total of 90 rechallenges were
identified in 80 patients. The progression-free survival at 6 months (PFS-6) was 48% in patients with
AG (12/25) and 27.7% in those with GBM (14/47). The PFS-6 was 16.7% in AG and 26.3% in GBM
for patients switched during TMZ and 57.9 and 28.6% in patients rechallenged after a TMZ-free interval
of at least 8 weeks. Relevant hematological toxicity (NCI-CTC grade 3-5) was observed in 22 of 90
rechallenges, and relevant non-hematological in ten of 90 rechallenges. Temozolomide was well
tolerated and generated promising PFS-6 in patients who had previously failed TMZ, regardless if they
progressed during TMZ treatment, or if they were rechallenged after a TMZ-free interval. These results
suggest that the TMZ rechallenge strategy warrants further investigation in a prospective randomized
trial.
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Abstract 
Background: Temozolomide (TMZ) is the standard of care for patients with 
newly diagnosed glioblastoma (GBM) as well as recurrent anaplastic glioma 
(AG) and GBM. It has become common practice to re-expose patients to TMZ 
previously treated with TMZ as well as even to switch to alternative dosing 
regimens of TMZ when patients relapse or progress on standard TMZ. There is 
so far scarce data on the efficacy of this therapeutic strategy currently referred 
to as TMZ rechallenge. 
Patients and Methods: A retrospective review of patients with recurrent glioma 
rechallenged with TMZ was conducted. Patients experiencing progressive 
disease (PD) during TMZ therapy who were rechallenged with alternative TMZ 
regimens and patients rechallenged after stable disease (SD) in a TMZ-free 
interval were evaluated separately.  
Results: A total of 90 rechallenges were identified in 80 patients. The 
progression-free survival at 6 months (PFS-6) was 48% in AG (12/25) and 
27.7% in GBM (14/47). PFS-6 was 16.7% in AG and 26.3% in GBM for patients 
switched during TMZ and 57.9% and 28.6% in patients rechallenged after a 
TMZ-free interval of at least 8 weeks. Relevant haematological toxicity (NCI-
CTC grade 3 to 5) was observed in 22 of 90 rechallenges, relevant non-
hematological in 10 of 90 rechallenges. 
Conclusions: TMZ was well tolerated and generated promising PFS-6 in 
patients who had previously failed TMZ, regardless if they progressed during 
TMZ treatment, or if they were rechallenged after a TMZ-free interval. The TMZ 
rechallenge strategy warrants further investigation in a prospective randomized 
trial. 
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Introduction 
Temozolomide (TMZ) is the drug of choice in the first-line radio-chemotherapy 
of glioblastoma (GBM) [1] as well as in the salvage therapy in recurrent GBM [2] 
and anaplastic glioma (AG) [3]. Whereas other effective regimens harbor 
cumulative toxicities that prevent extension of chemotherapy beyond 5 to 6 
cycles, no relevant cumulative toxicity has been reported in patients treated with 
up to 40 cycles of temozolomide [4]. These data render TMZ a good candidate 
for long-term therapy, e.g. when residual tumor persists after 6 cycles, or even 
for maintenance therapy in patients without measurable tumor. It can be 
speculated that this could improve the 12-months PFS rate of 26.9% of the 
EORTC/NCIC trial in patients with newly diagnosed GBM [1]. In that trial, about 
nine months (concomitant radio-chemotherapy and six cycles of adjuvant 
chemotherapy with TMZ) coincided with the end of chemotherapy. However, 
even after prolonged use of TMZ, all patients with high-grade gliomas 
eventually relapse. Although a large number of salvage therapies are used 
depending upon the clinical setting, none of these regimens is established as a 
standard. In addition, due to its incorporation into the first-line treatment of 
GBM, TMZ is considered by many investigators to be not longer a reasonable 
choice for patients with recurrent GBM. However, alternative schedules of TMZ 
addressing different pathophysiological mechanisms could be effective even 
after progression during standard TMZ regimens (“TMZ failure rechallenge”) 
and for rechallenge after a TMZ-free interval (“TMZ-free interval rechallenge”). 
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Therefore, there is an urgent clinical need to understand whether a rechallenge 
with TMZ, to date the most effective agent against gliomas, is active in patients 
with malignant gliomas. This issue has not been addressed in a larger series of 
patients. 
Selection of the most promising regimen for this approach is currently based on 
limited data. The standard regimen of TMZ at 150-200 mg/m2 body surface area 
on days 1-5 of a 28 day cycle [2, 3] is best analyzed and might be effective in 
patients who have progressed after a TMZ-free interval after initial stabilization 
of disease and termination of TMZ. However, if progression occurred during 
therapy with TMZ, it would be unreasonable to continue TMZ at the same 
regimen, i.e. the same dose at the same intervals. Therefore, various dosing 
schedules that increase the duration of exposure and the cumulative dose of 
TMZ, are currently being investigated for the treatment of recurrent glioma, in 
order to enhance antitumor activity and overcome resistance. 
In addition, there may be a benefit from alternative modes of action than the 
presumable cytotoxicity associated with the standard dose, e.g. antiangiogenic 
properties of a metronomic regimen, 20 mg total/day [5]. A “one week on / one 
week off” scheme (150 mg/m2 at days 1-7 and days 15-21, in a 28 day cycle) 
has been associated with considerable efficacy and was tolerated [6, 7]. 
Another alternative is an intensified 3 out of 4 weeks approach (75-100 mg/m2 
at days 1-21, in a 28 day cycle). This regimen may yield similar results with 
respect to efficacy, but a higher rate of toxicity, specifically lymphopenia and 
infection, have been reported [8, 9]. The latter two regimens aim at a dose 
intensification, which could enhance the direct cytotoxic effect of TMZ and 
which might deplete the DNA repair enzyme O6-methylguanine DNA 
 Hau, 5
methyltransferase (MGMT) [10]. This enzyme modulates resistance to alkylating 
chemotherapeutic agents [11].  
So far, two reports provide the first preliminary evidence of the potential efficacy 
of a TMZ rechallenge: in the first analysis, 14 patients with Grade III or IV 
gliomas were rechallenged with 150-200 mg/m2 TMZ in the standard schedule 
after progressing after an initial good response to TMZ [12]. The response rate 
(RR) was 29%, the stabilization rate 14%, and the median time to progression 
(mTTP) 14 weeks. In a series of 98 patients, with the “one week on / one week 
off” schedule in recurrent GBM, 9 patients were treated with standard dose TMZ 
at first line and were rechallenged with the dose intense TMZ regimen at the 
time of first progression. Although there were small numbers of patients, 
outcome data of rechallenged patients did not differ compared to the whole 
group [6].  
Based on the hypothesis that TMZ rechallenge may salvage some patients with 
disease progression during or after TMZ, we evaluated a dataset of 90 TMZ 
rechallenges in malignant glioma patients in 3 institutions, for toxicity and 
efficacy.  
 
Methods 
Study design and patients. A retrospective review of patients with recurrent 
glioma rechallenged with TMZ was performed in 3 institutions (Department of 
Neurology, University of Regensburg; Department of Neurology, University of 
Tübingen; Department of Neurooncology, University of Heidelberg, Germany). 
Patients with World Health Organization (WHO) grade III anaplastic 
astrocytoma (AG), anaplastic oligodendroglioma, and anaplastic 
oligoastrocytoma, or WHO grade IV (GBM or gliosarcoma) were included. 
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Patients with grade II glioma (including astrocytoma, oligoastrocytoma and 
oligodendroglioma) are reported for toxicity, but not for efficacy, because of the 
small numbers. Nine of the GBM patients were already included in a previous 
report [6]. 
This analysis was compiled from study and individual treatment patients, in 
which patients had consented to participate. All clinical trials involved in the 
primary treatment of patients were conducted after full approval and in 
accordance with the ethical standards of the responsible institutional (IRB or 
EC) national or European authorities. 
 
Treatment. Basic treatment guidelines for considering rechallenge were 
consistent at all 3 institutions: if patients relapsed more than 8 weeks after 
discontinuation of prior TMZ, they were treated with the same or an alternative 
regimen of TMZ; if they progressed while still receiving TMZ, they were treated 
with an alternative regimen. The following regimens were used for rechallenge: 
75 mg/m2/d on days 1-42 during radiotherapy plus maintenance, 150-200 
mg/m2/d day 1-5 / 28 days (“EORTC / NCIC” regimen); 150-200 mg/m2/d day 1-
5 / 28 days (“standard” regimen); 150 mg/m2/d day 1-7 and 15-21 / 28 days 
(“one week on / one week off” regimen); 75 mg/m2/d day 1-21 / 28 days; 
continuous 40 mg/d (“metronomic” regimen); or combinations of any adjuvant 
agent (PEG-liposomal doxorubicin or 13-cis retinoic acid) with one of the above 
listed TMZ regimens. 
 
Evaluation of toxicity and efficacy. In order to be included in this analysis, a full 
range of prospectively documented data needed to be available for analysis: 
demographic data; histology, extent of resection and radiotherapy in the first-
 Hau, 7
line and relapse setting; all prior chemotherapy regimens with dose 
modifications, reasons for discontinuation, and responses; doses, regimens, 
number of cycles, and duration of treatment with TMZ in the first line setting and 
at rechallenge; dates of diagnosis and progression under primary administration 
of TMZ and rechallenge; laboratory values, including full blood counts and C-
reactive protein for the evaluation of hematological toxicity and infective 
complications. An effort was made to determine the outcome of all patients. 
Toxicity was classified and graded using the National Cancer Institute Common 
Toxicity Criteria Version 3.0 (NCI-CTC) score, focusing on grade 1-5 toxicities 
for leukopenia, lymphopenia, thrombocytopenia, infections, nausea and 
vomiting and grade 3-5 for other toxicities during treatment with TMZ. Response 
evaluation by magnetic resonance imaging (MRI) using T1, T1 plus gadolinium, 
and T2 or FLAIR sequences was performed using standard Macdonald’s criteria 
for grade III and IV tumors [13]. Stable disease (SD) was defined as 
measurable stable disease or no progression after macroscopic complete 
resection.  
 
Statistical analysis. All data was entered into a database and analyzed 
statistically using JMP (JMP by SAS, Version 7.0). Response rates, progression 
free survival at 6 and 12 months (PFS-6/12), median time to progression 
(mTTP) after rechallenge with TMZ, and median overall survival (mOS) from 
TMZ rechallenge, from primary TMZ and from diagnosis are reported. TTP was 
defined as time from diagnosis or first day on TMZ as rechallenge, to the first 
signs of progression by MRI or clinical symptoms, whichever came first. OS was 
defined as time from diagnosis before 1st line therapy until death. Survival data 
were calculated according to the Kaplan-Meier method. Patients with TMZ 
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rechallenge at failure during TMZ (“TMZ failure rechallenge”) and rechallenge in 
a TMZ-free interval (“TMZ-free interval rechallenge”) were evaluated pooled and 
separately.  
 
Results 
Data collection and number of patients. All data were collected from patients 
(n=80) with grade II, III or IV gliomas who met the criteria of having complete 
data available and had at least one course of prior TMZ. All patients were 
treated between January 2000 and October 2007. Some patients received a 
rechallenge of TMZ more than once, so a total of 90 TMZ rechallenges were 
included. Thirteen patients had grade II, 22 grade III and 45 grade IV gliomas. 
Seven of the grade II (50%) and 12 of the grade III tumors (55%) harboured an 
oligodendroglial component.  
 
Demographic data. The median age of all patients was 48 years (41 for grade 
III, and 52 for grade IV; range: 19-69). At rechallenge, the mean numbers of 
previous resections and radiotherapies were two (range: 1-4) and one (range: 
1-3), respectively, and the median Karnofsky Performance Score (KPS) was 90 
(range: 30-100).  
 
Treatment regimens at primary and rechallenge TMZ. As part of first-line 
therapy, the following dosing regimens of TMZ were used: 75 mg/m2/d at days 
1-42 concomitant to radiotherapy (n=4); 75 mg/m2/d at days 1-42 during 
radiotherapy plus 150-200 mg/m2/d for 5/28 days (n=36), or 150-200 mg/m2/d 
for 5/28 days without concomitant TMZ during radiotherapy (n=38), 75 mg/m2/d 
for 21/28 days (n=1), or continuous TMZ at 40 mg/d (n=1).  
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Notably, 32% of the AG patients and 15% of GBM patients had a non-TMZ 
based salvage therapy between the first and second (rechallenge) treatment 
with TMZ. 
At rechallenge, patients received one of five TMZ regimens: 75 mg/m2/d at days 
1-42 during radiotherapy plus 150-200 mg/m2/d at 5/28 days (n=1), 150-200 
mg/m2/d at 5/28 days (n=43), 150 mg/m2/d at 7/14 days (n=33), 75 mg/m2/d at 
21/28 days (n=5), and continuous metronomic 40 mg/d (n=8). 79/90 (88%) of 
the rechallenge regimens consisted of a TMZ monotherapy. Eleven patients 
received TMZ combinations with 13-cis retinoic acid (n=5) or PEG-liposomal 
doxorubicin (n=6). Rechallenges with combinations of TMZ with radiotherapy 
(n=1), 13-cis retinoic acid (n=5) and PEG-liposomal doxorubicin (n=6) were kept 
within the analysis as they were small in number, and their TTP and OS were 
within the range of the respective entity group. 
 
Toxicity. All TMZ cycles for all patients treated at recurrence were assessed for 
toxicity. All TMZ-based regimens were well tolerated at rechallenge. There were 
no hematological or non-hematological grade 5 toxicities. Toxicity in patients 
treated with the 40 mg/d continous schedule (n=8) did not exceed grade 2. The 
dose-intense schedules had a comparable distribution of grade 1-4 toxicities 
(Table 1). Besides the adverse events shown in Table 1, diarrhoea, vertigo, 
taste alteration, constipation, meteorism, pruritus or transaminase elevation not 
exceeding grade 2 were noted in one patient each. 
Severe adverse events, defined as death, hospitalization or a grade 3/4 event 
with a ”likely“ attribution to TMZ occurred in 6 patients, with an average of 0.3 
events per patient over the treatment course. These events were attributable to 
the known bone marrow toxicity of TMZ or related problems (infection). One 
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patient experienced a pulmonary embolism. Patients with grade IV gliomas 
experienced a higher rate of severe adverse events, possibly related to the 
more malignant clinical course of disease in these patients.  
 
Therapy terminations. Primary TMZ was stopped due to tumor progression 
(n=30), end of a clinical study (n=24), patient wish (n=13) or toxicity (n=9); 5 
patients completed an individual treatment regimen as planned. 
Termination of TMZ rechallenge was due to toxicity (n=6/72, 8%), patients’ 
decision (n=6, 8%), end of study (n=3, 4%) or tumor progression (n=44, 61%) 
(Table 2). 
 
Efficacy. Outcomes after first-line treatment of TMZ in this group of patients 
were favorable. Response rates (RR; defined as CR or partial responses (PR), 
were 55% in grade III and 10% in grade IV gliomas; 32% and 62% of the 
patients experienced stable disease (SD). The mTTP was 77 weeks for grade 
III and 41 weeks for grade IV gliomas. Of note, only two patients in the grade III 
(2.1 and 3.6 months) as well as three patients in the grade IV glioma group (1.4, 
3.9 and 3.9 months) had an early progression on the first TMZ treatment.  
Before TMZ rechallenge, 57 patients received macroscopic complete or partial 
resections. Upon TMZ rechallenge, the RR was 32% in patients with grade III 
and 10.4% in patients with grade IV gliomas, and the rates of SD were 36% and 
58.3%. PFS-6 was 48% for patients with grade III and 27.7% for patients with 
grade IV gliomas, the respective values for the patients with “TMZ failure 
rechallenge” were 16.7% (AG) and 26.3% (GBM), and for “TMZ-free interval 
rechallenge” were 57.9% (AG) and 28.6% (GBM). There was a significantly 
better outcome in TTP (Chi2, Wilcoxon-test, p = 0.0473) in the grade III gliomas 
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retreated after a TMZ-free break (Figure 1 and Table 3). The respective data 
were not different in the grade IV gliomas between the subgroups (TTP: Chi2, 
Wilcoxon-test, p = 0.2706) (Figure 2 and Table 3). Importantly, no difference 
was seen for GBM patients on primary TMZ for ≤ 6 or > 6 months in the “TMZ-
failure” group (data not shown). 
The mOS from primary TMZ was 79.0 weeks for GBM and 180.1 weeks for AG; 
the mOS from diagnosis was 100.3 weeks for GBM and 289.9 weeks for AG. 
Interestingly, there was also an association of the timepoint of rechallenge with 
OS. In grade III gliomas, OS from rechallenge was significantly better in the 
subgroup of patients rechallenged after a TMZ-free break (Chi2, Wilcoxon-test, 
p = 0.0011) (Table 3).   
Comparing patients with GBM rechallenged at 150-200mg/m2/d at 5/28 days 
(n=15) after a TMZ-free interval of at least eight weeks or 150mg/m2/d at 7/14 
days (n=26) in the group progressing under TMZ, the mTTP was 24 and 22 
weeks, not indicating a relevant difference in these cohorts. The patient 
numbers in the other regimens were too small to compare. 
For the subset of grade III tumors with an oligodendroglial component, the PFS-
6 was 58.3%, and mTTP upon TMZ rechallenge was 38.6 weeks. It is important 
to note that these patients survived 87.9 weeks beyond TMZ rechallenge.  
 
Discussion 
Rechallenge is defined as the re-use of a therapeutic agent, which was used 
previously in the same patient. Rechallenge with TMZ is promising as the agent 
can be used in different heterogenous regimens and shows probably no 
cumulative toxicity. We show that a rechallenge with TMZ in patients with 
malignant gliomas is feasible and yields promising response rates, 
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stabilizations, and clinically meaningful prolongation of progression-free 
intervals. This holds true for rechallenges with alternative regimens of TMZ if 
the patient relapsed during TMZ treatment, and for rechallenges in a TMZ-free 
treatment period. To circumvent the issue of pseudoprogression, best defined 
as apparent radiographic disease progression immediately or within three 
months after a given (radiotherapy-containing) treatment that resolves without 
altering the treatment to stable or improved MRI [14], patients were preferably 
included not earlier than three months after the initiation of the prior TMZ 
treatments. Two patients included at < 2 months received a re-biopsy to confirm 
progressive disease. Further three patients included < 4 months from initiation 
of prior TMZ are performing similar to the overall cohort. 
The toxicity induced by TMZ rechallenge was in the range of the published 
primary and relapse TMZ data, which was in line with the experience that TMZ 
has probably no cumulative toxicity (Table 1) [1, 2, 3]. In addition, no secondary 
malignancies were reported in our cohort. In a subset of approximately 7% of 
patients, treatment was terminated because of toxicity. The discontinuation 
rates were comparable in the primary and rechallenge setting, which also 
emphasized the absence of cumulative toxicity of TMZ.  
Patients with high-grade gliomas responded unexpectedly well with response 
rates of 32% and 10.4% in patients with grade III and grade IV gliomas. PFS-6 
was 48% and 27.7%, and mTTP was 25.7 and 20.4 weeks. Looking at 
subgroups, results in tumors with an oligodendroglial component are, as 
expected, more promising than results in non-oligodendroglial tumors.  
To substantiate possible differences in the efficacy of rechallenges in patients 
who progressed under treatment with TMZ (“TMZ-failure rechallenge”) and 
patients who progressed after termination of primary TMZ in a TMZ-free 
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treatment interval (“TMZ-free interval rechallenge”), we evaluated these 
subgroups separatedly. A remarkable difference was seen only for the grade III 
gliomas in mTTP, PFS-6 and -12 and mOS (Table 3 and Figure 1). For the 
larger group of GBM patients, no relevant differences between both groups 
were detected. Here, it is tempting to speculate that our hypothesis, to use an 
alternative regimen in the TMZ-failure rechallenges to provide a meaningful 
efficacy of the TMZ rescue regimen, might be correct. This argues for an equal 
efficacy of TMZ rechallenge in both situations in GBM, provided that alternative 
regimens of TMZ are used in patients progressive under TMZ treatment. The 
significant difference in OS from rechallenge in grade III gliomas is most likely 
due to the TMZ rechallenge. Recognizing the retrospective nature and lack of a 
control group in these data, the efficacy none-the-less suggests that TMZ 
rechallenge is comparable with data from relapse trials utilizing different 
chemotherapy regimens. The response rate for TMZ in relapse of GBM 
reported by Yung et al. was 5.4% and the rate of stabilizations 40.2%, as 
compared to 10.4% and 58.3% in the present data. The PFS-6 was 21% in 
comparison to 27.7% in our cohort. Of note, 65% of the patients in that trial had 
been preexposed to nitrosoureas [2]. The favorable outcome in our patient 
population might be due to the implementation of dose-intense TMZ regimens 
as opposed to the standard 5 / 28 days regimen. The efficacy of alternative 
regimens, e.g. the “one week on/one week off” regimen is further substantiated 
by data, which suggest considerable efficacy of this regimen in recurrent GBM 
[6]. We have previously reported a PFS-6 of 44% in patients with relapse of 
high-grade gliomas, who were not pretreated with TMZ in the majority of cases. 
However, in patients with a TMZ-free interval rechallenge, the efficacy of the 
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TMZ rechallenge appeared not to differ between the approved 5 in 28 days 
regimen [2] vs. the “one week on / one week off” regimen [6].  
In 1999, a meta-analysis by Wong et al. [15] reported an overall RR of 6% and 
a PFS-6 of 15% in patients with recurrent GBM. Comparing the present data to 
this benchmark meta-analysis, our data warrant further substantiation in a 
randomized clinical trial. Patients with AG in that metaanalysis experienced a 
response rate of 14%, stabilizations of 48% and PFS-6 of 48%, which is in the 
range of our findings, 32%, 36% and 48% respectively. This is also the case for 
the PFS-6 of 46% reported in the trial leading to approval in AG [6]. 
We considered the retrospective nature of these data, a potential selection bias 
and the overall favourable median age (52 years) in the GBM cohort, which is 
slightly below the average, for this rechallenge patient population. Thus, in order 
to minimize biases, all consecutive patients treated within our institutions were 
included in the analyses and a thorough review of the patients’ original charts 
was undertaken. In addition, a recently published study defined prognostic 
groups in patients with relapse of high-grade glioma by means of a recursive 
partitioning analysis [16]. If the GBM patients from our evaluation were 
introduced according to their prognostic factors into this analysis, they should 
reach a mOS of 5.6-6.4 months; patients with grade III gliomas should reach a 
mOS of about 17 months. Considering that 32% of the grade III and 16% of our 
GBM patients were in second relapse at TMZ rechallenge, the outcomes in our 
cohort with a mOS from rechallenge of 16.7 and 5.9 months after TMZ 
rechallenge, is well within the expected range. 
The Canadian RESCUE study evaluates the concept of TMZ rechallenge with 
an alternative regimen of TMZ (28/28 days) after failure of primary TMZ. In this 
study, an effort was done to build three groups of patients that underwent 
 Hau, 15
rechallenge. Two groups are similar to our “TMZ-failure” and “TMZ-free 
rechallenge” groups. The PFS-6 rates of the RESCUE population are 23% and 
35% as compared to 26.3% and 28.6% in the present series. However, Perry et 
al. also defined a third group of patients that are a subgroup of the TMZ failure 
group with a primary TMZ exposure of more than 6 months. The latter group did 
poorly, with a PFS-6 of only 7% [17].  
The present study justifies (i) the initiation of a prospective, controlled trial 
analyzing rechallenge with intensified TMZ regimens in patients who progress 
while on TMZ therapy, or who progress after discontinuation of TMZ treatment. 
Furthermore, it indicates (ii) a role for rechallenge in a defined subset of patients 
without other approved options or experimental protocols.  
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Figure Legends 
 
Figure 1: PFS in the 25 rechallenges in grade III gliomas according to "TMZ-
failure rechallenge" (red) and "TMZ-free interval rechallenge" (blue). Confidence 
intervals at the 95% level are depicted by the hatched lines. 
 
Figure 2: PFS in the 47 rechallenges in grade IV gliomas according to "TMZ-
failure rechallenge" (red) and "TMZ-free interval rechallenge) (blue). Confidence 
intervals at the 95% level are depicted by the hatched lines. 
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Tables 
 
Table 1: Adverse events according to symptoms during rechallenge with temozolomide * 
 
AE (NCI-CTC Version 3.0) Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total 
Leukopenia 16      22 3 1 0 42
Lymphopenia 3    9 12 1 0 25 
Thrombopenia 24    3 2 3 0 32 
Infection 2    4 5 1 0 12 
Nausea/Vomiting 2    15 1 0 0 18 
Deep Vein Thrombosis 0    0 1 0 0 1 
Pulmonary Embolism 0    0 0 1 0 1 
Fatigue 0    8 1 0 0 9 
Total 47      61 25 7 0 140
 
* Data are presented separately for grades of toxicity graded according to NCI-CTC. 
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Table 2: Reason for discontinuation of therapy in rechallenge TMZ *  
 
Tumor Grade (WHO) III (n=25) IV (n=47) 
Tumor Progression (PD) 15  29
Treatment Completed 2  1
Patient Wish 4  2
Toxicity 1  5
n.a. 1  4
Ongoing 2  5
Other 0  1
 
* Data are presented separately for rechallenges in patients with AG (grade III) and GBM (grade IV). As most rechallenges were 
performed outside clinical studies, no strict criteria for termination of therapy due to toxicity were established. However, most patients 
discontinued therapy after toxicity grade 4 or repeated toxicities grade 3 (CTC, Version 3.0). Some of the analyzed patients are still 
under treatment („ongoing“). Legend: n.a.= not assessable.  
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Table 3: Efficacy of rechallenge TMZ * 
  all Rechallenges 
„TMZ-failure 
rechallenge“ 
„TMZ-free interval 
rechallenge“ 
Patient numbers WHO °III (n) 25   6 19
       WHO °IV (n) 47 19 28
mTTP from Rechallenge WHO °III (weeks) 25.7   12.6 33.0
      WHO °IV (weeks) 20.4 17.9 21.3
mOS from Rechallenge WHO °III (weeks) 71.3   44.4 82.4
      WHO °IV (weeks) 24.7 28.2 22.9
PFS-6 from Rechallenge     WHO °III (%) 48.0 16.7 57.9
       WHO °IV (%) 27.7 26.3 28.6
PFS-12 from Rechallenge WHO °III (%) 24.0   16.7 26.3
       WHO °IV (%) 10.6 5.3 14.3
RR [CR, PR] at Rechallenge     WHO °III (%) 32.0 33.3 31.6
       WHO °IV (%) 10.4 0.0 17.2
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SD at Rechallenge      WHO °III (%) 36.0 33.3 36.8
       WHO °IV (%) 58.3 68.4 51.7
 
* Efficacy at TMZ rechallenge is presented for patients with AG (grade III) and GBM (grade IV). Furthermore, data are shown for 
rechallenges in all situations (“all”), if PD occurred during primary therapy with TMZ (“TMZ-failure rechallenge“), and if tumors recurred 
in a TMZ-free interval (“TMZ-free interval rechallenge”). Legend: mTTP = median time to progression; mOS = median overall survival; 
PFS-6/-12 = progression free survival at 6/12 months; RR = response rate; CR = complete response PR = partial response; SD = 
stable disease; n = number; PD = progressive disease; TMZ = temozolomide. 
 
 
